Escitalopram-induced hepatitis: A case report

doi:10.12998/wjcc.v10.i8.2468

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 8

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8604)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-3) series.

Item

Count

PDF

249

WORD

128

HTML

7170

Tables (1-3)

238

Sum=7785

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

255

Download

564

Sum=819

Mar 16, 2022 (publication date) through May 28, 2024

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Clin Cases. Mar 16, 2022; 10(8): 2468-2473
Published online Mar 16, 2022. doi: 10.12998/wjcc.v10.i8.2468

Table 3 Reporting odds ratio of acute hepatitis and cholestasis in Vigibase^® in patients receiving escitalopram

	OR	95% CI	P value
Acute hepatitis	1.938	1.186-3.166	0.0083
Cholestasis	1.866	1.279-2.724	0.0012

OR: Odds ratio; CI: Confidence interval.

Citation: Wabont G, Ferret L, Houdre N, Lepied A, Bene J, Cousein E. Escitalopram-induced hepatitis: A case report. World J Clin Cases 2022; 10(8): 2468-2473
URL: https://www.wjgnet.com/2307-8960/full/v10/i8/2468.htm
DOI: https://dx.doi.org/10.12998/wjcc.v10.i8.2468